In human cells, receptor-interacting protein kinase 2 (RIPK2) is mainly known to mediate downstream enzymatic cascades from the nucleotide-binding oligomerization domain-containing receptors 1 and 2 (NOD1/2), which are regulators of pro-inflammatory signaling. Thus, the targeted inhibition of RIPK2 has been proposed as a pharmacological strategy for the treatment of a variety of pathologies, in particular inflammatory and autoimmune diseases. In this work, we designed and developed novel thieno[2,3d]pyrimidine derivatives, in order to explore their activity and selectivity as RIPK2 inhibitors. Primary in vitro evaluations of the new molecules against purified RIPKs (RIPK1-4) demonstrated outstanding inhibitory potency and selectivity for the enzyme RIPK2. Moreover, investigations for efficacy against the RIPK2-NOD1/2 signaling pathways, conducted in living cells, showed their potency could be tuned towards a low nanomolar range. This could be achieved by solely varying the substitutions at position 6 of the thieno[2,3d]pyrimidine scaffold. A subset of lead inhibitors were ultimately evaluated for selectivity against 58 human kinases other than RIPKs, displaying great specificities. We therefore obtained new inhibitors that might serve as starting point for the preparation of targeted tools, which could be useful to gain a better understanding of biological roles and clinical potential of RIPK2.
16 May 2022 in Beilstein Journal of Organic Chemistry
The only known sulfur-containing karrikin, 3-methyl-2H-thiopyrano[3,4-b]furan-2-one, has been recently identified as an extremely efficient neuroprotective butenolide. Herein, we report the targeted synthesis of this compound as well as new synthetic protocols toward a class of compounds derived from 2H-furo[2,3-c]pyran-2-ones (karrikins) via bioisosteric exchange of oxygen with sulfur. In particular, we present synthetic procedures toward bioisosteres of karrikins with one or two sulfur heteroatoms incorporated into the core backbone together with evaluation of their biological activity in inhibition of acetylcholinesterase.
11 August 2026 in European Journal of Medicinal Chemistry
Methyltransferases (MTases) play central roles in numerous biological processes and have emerged as attractive therapeutic targets in a wide range of diseases. METTL21A is a protein lysine MTase responsible for the trimethylation of HSP70 family members. Moreover, METTL21A is overexpressed in hepatocellular carcinoma (HCC), where overexpression correlates with poor clinical outcome. Despite its biological and clinical relevance, small-molecule inhibitors of METTL21A remain largely unexplored. Here, we report the identification of 6d as a METTL21A inhibitor and the subsequent structure-activity relationship (SAR) study of analogues decorated with various fluorinated substituents, leading to metabolically stable 6n (HK262) with an IC50 1.10 μM. We solved a crystal structure of METTL21A in complex with 6m (HK474), providing structural insight into ligand recognition and supporting further structure-guided optimization. These findings establish a biochemically and structurally validated starting point for probing METTL21A function and a foundation for the development of cellularly active METTL21A-targeted chemical tools.